Benedek I H, Fiske W D, Griffen W O, Bell R M, Blouin R A, McNamara P J
Br J Clin Pharmacol. 1983 Dec;16(6):751-4. doi: 10.1111/j.1365-2125.1983.tb02258.x.
Although clinically relevant, drug-protein interactions in the morbidly obese population have not been studied thoroughly. The objective of this study was to evaluate serum chemistry profiles and the degree of serum protein binding of propranolol, diazepam and phenytoin in the serum of four female, morbidly obese (greater than 190% of ideal body weight) and eight control female subjects. Serum triglyceride concentrations were higher and high-density lipoproteins were lower in the obese subjects than in the control group. Serum albumin and total protein concentrations in the obese were not different from controls. Unexpectedly, alpha 1-acid glycoprotein concentrations were doubled in the obese subjects (mean obese value 121 mg/100 ml vs 62.9 mg/100 ml for the control subjects). Obese subjects had a mean fraction unbound (fu) for propranolol of 0.086, which was significantly different from the controls (fu = 0.123). The binding of diazepam was decreased slightly in the obese subjects. The binding of phenytoin was similar in both groups. The altered serum chemistry of obesity may play a significant role in the drug management of the obese patient by altering drug-protein interactions.
尽管具有临床相关性,但病态肥胖人群中的药物 - 蛋白质相互作用尚未得到充分研究。本研究的目的是评估4名病态肥胖(超过理想体重的190%)女性和8名对照女性受试者血清中普萘洛尔、地西泮和苯妥英的血清化学谱以及血清蛋白结合程度。肥胖受试者的血清甘油三酯浓度较高,高密度脂蛋白较低,与对照组相比。肥胖者的血清白蛋白和总蛋白浓度与对照组无差异。出乎意料的是,肥胖受试者的α1 - 酸性糖蛋白浓度增加了一倍(肥胖者平均数值为121 mg/100 ml,而对照受试者为62.9 mg/100 ml)。肥胖受试者普萘洛尔的平均未结合分数(fu)为0.086,与对照组有显著差异(fu = 0.123)。肥胖受试者中地西泮的结合略有下降。两组中苯妥英的结合相似。肥胖引起的血清化学变化可能通过改变药物 - 蛋白质相互作用在肥胖患者的药物管理中发挥重要作用。